These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 27717163)

  • 21. Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier.
    Watchorn J; Clasky AJ; Prakash G; Johnston IAE; Chen PZ; Gu FX
    ACS Biomater Sci Eng; 2022 Apr; 8(4):1396-1426. PubMed ID: 35294187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanocrystals Technology for Transdermal Delivery of Water-Insoluble Drugs.
    Liu Y; Zhao J; Wang L; Yan B; Gu Y; Chang P; Wang Y
    Curr Drug Deliv; 2018; 15(9):1221-1229. PubMed ID: 29779482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceutical nanocrystals: production by wet milling and applications.
    Malamatari M; Taylor KMG; Malamataris S; Douroumis D; Kachrimanis K
    Drug Discov Today; 2018 Mar; 23(3):534-547. PubMed ID: 29326082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
    Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
    Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nanosuspensions technology as a master key for nature products drug delivery and In vivo fate.
    Ma Y; Cong Z; Gao P; Wang Y
    Eur J Pharm Sci; 2023 Jun; 185():106425. PubMed ID: 36934992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations.
    Leone F; Cavalli R
    Expert Opin Drug Deliv; 2015; 12(10):1607-25. PubMed ID: 25960000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanosuspensions as a versatile carrier based drug delivery system--an overview.
    Sudhakar B; NagaJyothi K; Murthy KV
    Curr Drug Deliv; 2014; 11(3):299-305. PubMed ID: 24655052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Solution calorimetry as an alternative approach for dissolution testing of nanosuspensions.
    Kayaert P; Li B; Jimidar I; Rombaut P; Ahssini F; Van den Mooter G
    Eur J Pharm Biopharm; 2010 Nov; 76(3):507-13. PubMed ID: 20887787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects.
    Wong J; Brugger A; Khare A; Chaubal M; Papadopoulos P; Rabinow B; Kipp J; Ning J
    Adv Drug Deliv Rev; 2008 May; 60(8):939-54. PubMed ID: 18343527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanosuspension-Based Drug Delivery Systems for Topical Applications.
    Aldeeb MME; Wilar G; Suhandi C; Elamin KM; Wathoni N
    Int J Nanomedicine; 2024; 19():825-844. PubMed ID: 38293608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colloidal polymeric nanoparticles and brain drug delivery.
    Khalil NM; Mainardes RM
    Curr Drug Deliv; 2009 Jul; 6(3):261-73. PubMed ID: 19604140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulation aspects of intravenous nanosuspensions.
    Patel D; Zode SS; Bansal AK
    Int J Pharm; 2020 Aug; 586():119555. PubMed ID: 32562654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.
    Lai SK; Wang YY; Hanes J
    Adv Drug Deliv Rev; 2009 Feb; 61(2):158-71. PubMed ID: 19133304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Technological strategies to estimate and control diffusive passage times through the mucus barrier in mucosal drug delivery.
    Newby JM; Seim I; Lysy M; Ling Y; Huckaby J; Lai SK; Forest MG
    Adv Drug Deliv Rev; 2018 Jan; 124():64-81. PubMed ID: 29246855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery.
    Brough C; Williams RO
    Int J Pharm; 2013 Aug; 453(1):157-66. PubMed ID: 23751341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Has nanotechnology led to improved therapeutic outcomes?
    Bosselmann S; Williams RO
    Drug Dev Ind Pharm; 2012 Feb; 38(2):158-70. PubMed ID: 22191583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucus models to evaluate the diffusion of drugs and particles.
    Lock JY; Carlson TL; Carrier RL
    Adv Drug Deliv Rev; 2018 Jan; 124():34-49. PubMed ID: 29117512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in the study of drug nanocrystals.
    Shi J; Guo F; Zheng A; Zhang X; Sun J
    Pharmazie; 2015 Dec; 70(12):757-64. PubMed ID: 26817271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced pulmonary delivery of fluticasone propionate in rodents by mucus-penetrating nanoparticles.
    Popov A; Schopf L; Bourassa J; Chen H
    Int J Pharm; 2016 Apr; 502(1-2):188-97. PubMed ID: 26902722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanocrystals based mucosal delivery system: research advances.
    Liu Y; Shuai S; Huang G; Chen Y; Shen B; Yue P
    Drug Dev Ind Pharm; 2021 Nov; 47(11):1700-1712. PubMed ID: 35287534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.